Anticorpo monoclonal isolado anti-molécula de orientação repulsiva a
anticorpos monoclonais contra proteina rgm a e usos destes. a presente invenção refere-se a proteínas isoladas, particularmente anticorpos monocionais, que ligam e neutralizam a proteína rgm a. de modo específico, esses anticorpos têm a capacidade de inibirem a ligação de rgm a a seu receptor e/ou c...
Saved in:
Main Authors | , , , , , |
---|---|
Format | Patent |
Language | Portuguese |
Published |
15.03.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | anticorpos monoclonais contra proteina rgm a e usos destes. a presente invenção refere-se a proteínas isoladas, particularmente anticorpos monocionais, que ligam e neutralizam a proteína rgm a. de modo específico, esses anticorpos têm a capacidade de inibirem a ligação de rgm a a seu receptor e/ou co-receptores. esses anticorpos ou porções destes da invenção são úteis para determinar rgm a e inibir a atividade de rgm a, por exemplo, em um individuo que sofre de um distúrbio que inclui, mas não se limita a, esclerose múltipla, trauma cerebral de mamíferos, lesão da medula espinhal, derrame, doenças neurodegenerativas e esquizofrenia.
The subject invention relates to monoclonal antibodies which bind and neutralize RGM A protein. Specifically, these antibodies have the ability to inhibit the binding of RGM A to its receptor and/or coreceptors. These antibodies or antigen binding fragments thereof of the invention are useful for detecting RGM A and for inhibiting RGM A activity, for example in a human suffering from a disorder including but not limited to multiple sclerosis, mammalian brain trauma, spinal cord injury, stroke, neurodegenerative diseases, and schizophrenia. |
---|---|
AbstractList | anticorpos monoclonais contra proteina rgm a e usos destes. a presente invenção refere-se a proteínas isoladas, particularmente anticorpos monocionais, que ligam e neutralizam a proteína rgm a. de modo específico, esses anticorpos têm a capacidade de inibirem a ligação de rgm a a seu receptor e/ou co-receptores. esses anticorpos ou porções destes da invenção são úteis para determinar rgm a e inibir a atividade de rgm a, por exemplo, em um individuo que sofre de um distúrbio que inclui, mas não se limita a, esclerose múltipla, trauma cerebral de mamíferos, lesão da medula espinhal, derrame, doenças neurodegenerativas e esquizofrenia.
The subject invention relates to monoclonal antibodies which bind and neutralize RGM A protein. Specifically, these antibodies have the ability to inhibit the binding of RGM A to its receptor and/or coreceptors. These antibodies or antigen binding fragments thereof of the invention are useful for detecting RGM A and for inhibiting RGM A activity, for example in a human suffering from a disorder including but not limited to multiple sclerosis, mammalian brain trauma, spinal cord injury, stroke, neurodegenerative diseases, and schizophrenia. |
Author | Eve H. Barlow Schmidt Martin Mary R. Leddy Hsieh Chungming Bernhard K. Müller Phillip D. Bardwell |
Author_xml | – fullname: Eve H. Barlow – fullname: Hsieh Chungming – fullname: Bernhard K. Müller – fullname: Phillip D. Bardwell – fullname: Schmidt Martin – fullname: Mary R. Leddy |
BookMark | eNqNyjsOwjAMgOEMMPC6gxfGSk3aC7SIx4zYKys1UiTXjpqWCzEgzpGLwcABmP7h-9dmISq0MudGpuB1jAqDinpWQYaQlLFXwC8Wg3J--5kRegIdA8mE-ZWfCiPFmVN4IODWLO_IiXa_bsz-dLwdLgVF7ShF9CQ0de3VOldaV5Z1VdvWVv9-H062OXo |
ContentType | Patent |
DBID | EVB |
DatabaseName | esp@cenet |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Sciences |
ExternalDocumentID | BR122012004341B1 |
GroupedDBID | EVB |
ID | FETCH-epo_espacenet_BR122012004341B13 |
IEDL.DBID | EVB |
IngestDate | Fri Jul 19 14:22:09 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | Portuguese |
LinkModel | DirectLink |
MergedId | FETCHMERGED-epo_espacenet_BR122012004341B13 |
Notes | Application Number: BR20121204341 |
OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220315&DB=EPODOC&CC=BR&NR=122012004341B1 |
ParticipantIDs | epo_espacenet_BR122012004341B1 |
PublicationCentury | 2000 |
PublicationDate | 20220315 |
PublicationDateYYYYMMDD | 2022-03-15 |
PublicationDate_xml | – month: 03 year: 2022 text: 20220315 day: 15 |
PublicationDecade | 2020 |
PublicationYear | 2022 |
RelatedCompanies | ABBVIE INC ABBOTT LABORATORIES ABBOTT GMBH & CO. KG |
RelatedCompanies_xml | – name: ABBOTT LABORATORIES – name: ABBVIE INC – name: ABBOTT GMBH & CO. KG |
Score | 3.235834 |
Snippet | anticorpos monoclonais contra proteina rgm a e usos destes. a presente invenção refere-se a proteínas isoladas, particularmente anticorpos monocionais, que... |
SourceID | epo |
SourceType | Open Access Repository |
SubjectTerms | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
Title | Anticorpo monoclonal isolado anti-molécula de orientação repulsiva a |
URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220315&DB=EPODOC&locale=&CC=BR&NR=122012004341B1 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhR1dS8Mw8BhT1Dedip8jD9q3Iu2SbX0oYtvVIeyDMmVvI21TKNSmbJ3-IB_E37E_5qVsfrzoW0jCkVzucrnLfQBcJaFgrVgw3bI41SljXOecos7TZibtWkkUJcoOORi2-4_0YcqmNcg3sTBVntDXKjkiclSE_F5W93XxbcTyKt_KxU2YYpe89Se2p621Y9NURQs0z7F745E3cjXXtZ1AGwa2gUOGogi8tR3UlrbUU1rl2u89OSoypfgpVvx92B4jxLw8gFpRNmDX3VRfa8DOYP3pjc01_y0O4f4ux4NWyYcJko-MMvWOJinSD48lQSSl-rPMVh_KuZTEgsh5Fe64el-9STIXxTJbpC-c8CO49nsTt6_jimZfKJg5we8NtI6hnstcnABhgoc85i3DSAQ1uRXGyII0CdsoiDuduHsKzb9hnf034Rz2FGqV55XBLqBezpfiEkVxGTYr_H0ClQKOnQ |
link.rule.ids | 230,309,786,891,25594,76906 |
linkProvider | European Patent Office |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhR3LTsMwzJoGYtxggHiOHKC3CrVLtvVQIdpuDNhL00C7TWmbSpVGU20dfBAHxHfsx3CqjccFblESWYljx7HjB8BF5AtWDQXTLYtTnTLGdc4p6jw1ZtKGFQVBpOyQ3V6t_Ujvx2xcgGQdC5PnCX3NkyMiRwXI71l-X6ffRiwv962cX_kxdsnr1sj2tJV2bJqqaIHmOXZz0Pf6rua6tjPUekPbwCFDUQTe2g5qSxt1laFXPZ-eHBWZkv4UK60d2BwgxCTbhUKalaHkrquvlWGru_r0xuaK_-Z7cHuT4EGr5MMEyUcGU_WOJjHSDw8lQSTF-rOcLj-UcykJBZGzPNxx-b58k2Qm0sV0Hr9wwvfhstUcuW0dVzT5QsHEGf7eQPUAiolMxCEQJrjPQ141jEhQk1t-iCxII7-GgrheDxtHUPkb1vF_E86h1B51O5POXe_hBLYVmpUXlsFOoZjNFuIMxXLmV3JcfgJpqJGK |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Anticorpo+monoclonal+isolado+anti-mol%C3%A9cula+de+orienta%C3%A7%C3%A3o+repulsiva+a&rft.inventor=Eve+H.+Barlow&rft.inventor=Hsieh+Chungming&rft.inventor=Bernhard+K.+M%C3%BCller&rft.inventor=Phillip+D.+Bardwell&rft.inventor=Schmidt+Martin&rft.inventor=Mary+R.+Leddy&rft.date=2022-03-15&rft.externalDBID=B1&rft.externalDocID=BR122012004341B1 |